Zobrazeno 1 - 10
of 15
pro vyhledávání: '"L. N. Konovalova"'
Autor:
A. V. Rudakova, S. M. Kharit, I. V. Babachenko, L. N. Konovalova, S. V. Rychkova, A. N. Uskov, Yu. V. Lobzin
Publikováno v:
Журнал инфектологии, Vol 13, Iss 3, Pp 114-119 (2021)
Varicella is a significant burden on society and the healthcare system.Objective: to analyze the cost effectiveness of universal vaccination of children against varicella.Material and methods. The analysis was carried out from the perspective of the
Externí odkaz:
https://doaj.org/article/ee8840abe2ea414b89db3b94585bf130
Autor:
A. V. Rudakova, D. M. Danilenko, D. A. Lioznov, L. S. Karpova, S. M. Kharit, E. V. Mikitenko, A. N. Uskov, A. S. Kolbin, L. N. Konovalova, Yu. V. Lobzin
Publikováno v:
Журнал инфектологии, Vol 11, Iss 1, Pp 92-97 (2019)
According to requirements of WHO, the trivalent influenza vaccines (TIV) have to contain antigens of two influenza A strains (A/H1N1, A/H3N2) and one influenza B strain which can be presented by antigens of a virus of lineages Yamagata or Victoria. I
Externí odkaz:
https://doaj.org/article/0cf0e1fcd14f46e5b7d60c13812f894f
Publikováno v:
Журнал инфектологии, Vol 9, Iss 2, Pp 101-110 (2017)
Interferon-free therapy for genotype 1 hepatitis C are preferable from the point of view of clinical effectiveness and safety.The purpose of work was the assessment of costs and costeffectiveness of regimens for the treatment of HCV (1 genotype) at t
Externí odkaz:
https://doaj.org/article/6dcc239343f1410c919140383db668cc
Publikováno v:
Журнал инфектологии, Vol 9, Iss 2, Pp 17-22 (2017)
Now WHO experts annually formulates references on structure of both the 3rd, and 4 valent vaccines against influenza applied worldwide.The purpose of work was the assessment of averted costs due to influenza vaccination with trivalent and quadrivalen
Externí odkaz:
https://doaj.org/article/af25cc1ed111401bbc82d1e4b7961720
Publikováno v:
Журнал инфектологии, Vol 9, Iss 1, Pp 100-103 (2017)
The incidence of chronic hepatitis C inRussiais extremely high, that requires an increase the access to effective treatment regimens.The aim of the study is to assess the cost of HCV therapy (genotype 1) of naïve patients without cirrhosis with seco
Externí odkaz:
https://doaj.org/article/4097a9b5a42043f2badc5e133361a618
Publikováno v:
Журнал инфектологии, Vol 8, Iss 3, Pp 122-125 (2016)
In the treatment of chronic hepatitis C (CHC) protease inhibitors (PI) are actively used. The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and r
Externí odkaz:
https://doaj.org/article/220e7e7a5aa84b31876844da3c209666
Publikováno v:
Журнал инфектологии, Vol 8, Iss 1, Pp 79-82 (2016)
The protease inhibitors (PI) actively using for the treatment of chronic hepatitis C (CHC).The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and
Externí odkaz:
https://doaj.org/article/608a3e00a80941cd90d0626472890db0
Autor:
T. L. Nechayeva, M. Y. Zubova, T. S. Stakheyeva, O. G. Vasilieva, L. N. Konovalova, N. V. Zagoskina
Publikováno v:
Subtropical and ornamental horticulture. :66-74
Publikováno v:
Applied Biochemistry and Microbiology. 57:800-807
Autor:
Yu. V. Lobzin, A. V. Rudakova, A. N. Uskov, I. V. Babachenko, S. V. Rychkova, L. N. Konovalova, S.M. Kharit
Publikováno v:
Žurnal Infektologii, Vol 13, Iss 3, Pp 114-119 (2021)
Varicella is a significant burden on society and the healthcare system.Objective: to analyze the cost effectiveness of universal vaccination of children against varicella.Material and methods. The analysis was carried out from the perspective of the